全球动物炭疽疫苗市场规模（按产品、应用、分销管道、区域范围和预测）

动物炭疽疫苗市场规模及预测

2024 年兽用炭疽疫苗市场规模价值 91.4 亿美元，预计到 2032 年将达到 158.3 亿美元，预测期内（2026-2032 年）的复合年增长率为 10.6%。

炭疽疫苗产业规模的扩大归因于研发活动投资的增加、新进业者的加入、产品创新、技术突破、有效的资源配置，以及竞争对手之间为扩大地域和基本客群加剧的竞争。在不久的将来，政府政策和奖励、有利的法律​​法规预计将推动炭疽疫苗市场的成长。可支配收入的增加将提高消费者的消费能力，这将有助于炭疽疫苗市场的发展。全球炭疽疫苗市场报告对市场进行了全面的评估。它全面分析了关键细分市场、趋势、市场驱动因素、限制因素、竞争格局以及在市场中发挥关键作用的因素。

推动全球动物炭疽疫苗市场的因素

兽用炭疽疫苗市场的驱动因素受多种因素影响，包括：

• 炭疽菌发病率不断上升：炭疽菌在牲畜和野生动物群体中爆发的频率在许多地区仍然令人担忧。因此，需要製定和实施有效的疫苗接种计划，以防止炭疽病在牲畜中传播，保护人类和牲畜的健康。
• 政府措施：政府机构和兽医部门经常实施疫苗接种计划，以控制和预防炭疽病疫情。政府在疫苗生产、采购和研发方面的投入推动了兽医行业对炭疽疫苗的需求。
• 不断扩张的畜牧业：随着世界人口的成长，对肉类、乳品和皮革等动物衍生产品的需求也随之成长。畜牧业的扩张增加了对炭疽菌疫苗的需求，以保护动物免受疾病爆发的侵害，并维持稳定安全的食品供应链。
• 知识与教育：兽医专业人员和畜牧生产者对炭疽菌感染风险的认识不断提高，有助于推动积极的疫苗接种计划。由于进行了宣传工作，强调了疫苗接种在控制炭疽菌疫情的价值，市场规模不断扩大。
• 技术发展：生物技术和疫苗配方的进步使得开发更安全、更有效的炭疽菌疫苗成为可能。佐剂和创新的给药方法增强了免疫力，提高了疫苗效力，从而提高了兽医的疫苗接种率。
• 全球化与贸易：随着全球牛及牲畜产品贸易量的不断增长，人们越来越重视疾病的防治，以遵守法规并维持贸易的连续性。炭疽菌疫苗接种计划对于满足这些要求并增加市场需求至关重要。
• 疫情防治：炭疽菌是一种生物性危害，在某些地缘政治环境下可能会被人为释放。各国政府和兽医机构采购炭疽菌疫苗，作为应对生物恐怖主义风险和保护公众健康的防控措施的一部分。

限制全球动物炭疽疫苗市场的因素

多种因素可能对动物炭疽疫苗市场造成限製或挑战。这些因素包括：

• 某些领域的知识有限：有关炭疽菌和疫苗接种价值的知识可能有限，特别是在基础设施和资源有限的较贫穷国家，这可能会阻碍炭疽菌疫苗的广泛采用并限制某些地区的市场扩张。
• 监管障碍：动物疫苗的监管审批成本高且耗时。安全性、有效性和品管方面的监管力度加大，可能会使小型疫苗开发商难以进入市场，从而限制竞争和创新。
• 疫苗分发和储存挑战：炭疽菌疫苗通常需要特殊的储存条件，例如冷藏，才能维持其有效性。在没有低温运输基础设施的地区，确保疫苗的妥善储存和分发在后勤方面具有挑战性，这可能会影响疫苗的有效性和可用性。
• 低风险认知：畜牧生产者和兽医专业人员可能认为，在炭疽病疫情罕见或不规则的地区，感染炭疽菌的可能性很小。这可能会导致自满情绪，并减少对炭疽菌疫苗的需求，尤其是在炭疽病不太常见的情况下。
• 成本问题：农民接种炭疽疫苗的决定可能会受到疫苗相关成本的影响，包括疫苗成本、疫苗供应成本和兽医服务成本。在财政状况不佳或优先事项相互衝突的地区，成本效益的考量可能会阻碍炭疽疫苗的普及。
• 保护效力和持续时间：儘管疫苗技术不断进步，但炭疽疫苗的保护效力和持续时间仍存在疑问。加强剂量的需求以及疫苗效力的差异性可能会影响疫苗的接种率以及疫苗在市场上的普遍普及度。
• 有效的生物安全措施：除了疫苗接种计画外，预防牛炭疽菌疫情也至关重要。不良的生物安全措施，例如胴体处理不当或检疫通讯协定不完善，可能会削弱疫苗宣传活动的有效性。

目录

第一章动物炭疽疫苗全球市场介绍

• 市场概览
• 研究范围
• 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

• 资料探勘
• 验证
• 第一手资料
• 资料来源列表

第四章动物炭疽疫苗全球市场展望

• 概述
• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 波特五力模型
• 价值链分析

5. 全球动物性炭疽疫苗市场（按产品）

• 概述
• 无细胞PA疫苗
• 活病毒疫苗

6. 全球动物性炭疽疫苗市场（依应用）

• 概述
• 对于动物
• 对人类来说

7. 全球动物炭疽疫苗市场（依分销管道）

• 概述
• 医院药房
• 零售药局
• 其他的

8. 全球动物性炭疽疫苗市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区
  • 拉丁美洲
  • 中东和非洲

9. 全球动物性炭疽疫苗市场竞争格局

• 概述
• 各公司市场排名
• 主要发展策略

第十章 公司简介

• Ceva Sante Animale
• Bayer Sanidad Animal
• Central Veterinary Control and Research Institute
• Agrovet
• Colorado Serum Company
• Empresa Colombiana De Productos Veterinarios SA
• Biogenesis Bago SA
• Indian Immunologicals Limited
• Botswana Vaccine Institute
• Centro Diagnostico Veterinario

第十一章 公司简介 附录

• 相关调查

Veterinary Anthrax Vaccines Market Size And Forecast

Veterinary Anthrax Vaccines Market size was valued at USD 9.14 Billion in 2024 and is projected to reach USD 15.83 Billion by 2032, growing at a CAGR of 10.6% during the forecasted period 2026 to 2032.

The increase in the size of the anthrax vaccines industry can be attributed to rising investments in R&D activities, the entry of new players, product innovation, technological breakthroughs, effective resource allocation, and growing competition among business rivals to expand its regional and customer base. Government policies and incentives, as well as favorable legislation, are expected to drive the growth of the Veterinary Anthrax Vaccines Market in the near future. Customers' spending power will expand as their disposable income rises, contributing to the market profits for anthrax vaccinations. The Global Veterinary Anthrax Vaccines Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Veterinary Anthrax Vaccines Market Drivers

The market drivers for the Veterinary Anthrax Vaccines Market can be influenced by various factors. These may include:

• Rising Anthrax Incidences: In many areas, there is still concern over the frequency of anthrax in livestock and wildlife populations. This makes it necessary to create and implement efficient vaccination programmes in order to prevent the disease from spreading among animals and protect the health of both humans and animals.
• Government Initiatives: To manage and prevent anthrax outbreaks, vaccination programmes are frequently implemented by government agencies and veterinary authorities. Government investments in vaccine production, procurement, and research and development are what fuel the veterinary industry's demand for anthrax vaccinations.
• Expanding Livestock Industry: As the world's population rises, so does the need for goods generated from animals, like meat, milk, and leather. The necessity for anthrax vaccinations to safeguard animal populations against disease outbreaks and maintain a stable and secure food supply chain is increased by the expansion of the livestock industry.
• Knowledge and Education: Proactive immunisation programmes are encouraged by veterinary professionals and livestock farmers' heightened knowledge of the dangers of anthrax infection. The market is growing as a result of education initiatives emphasising the value of immunisation in halting anthrax outbreaks.
• Technological Developments: The development of safer and more effective anthrax vaccinations has been made possible by advances in biotechnology and vaccine formulation methods. Adjuvants and innovative delivery methods extend immunity and improve vaccine efficacy, which increases vaccination rates among veterinarians.
• Globalisation and Trade: In order to comply with regulations and maintain trade continuity, there is a greater emphasis on disease prevention and control as global traffic in cattle and animal products grows. Programmes for immunisation against anthrax are essential for fulfilling these conditions and increasing market demand.
• Preparedness for Outbreaks: Anthrax is still a biological hazard that might be intentionally released in specific geopolitical situations. Vaccinations against anthrax are purchased by governments and veterinary agencies as part of their readiness measures to counter bioterrorism risks and protect public health.

Global Veterinary Anthrax Vaccines Market Restraints

Several factors can act as restraints or challenges for the Veterinary Anthrax Vaccines Market. These may include:

• Limited Knowledge in Some Areas: There may not be enough knowledge about anthrax and the value of vaccination in some areas, especially in poor nations with little infrastructure and resources. This may prevent the spread of anthrax vaccinations and restrict market expansion in certain regions.
• Regulatory Obstacles: Veterinary vaccination regulatory clearances can be expensive and time-consuming. Stricter safety, efficacy, and quality control regulations could make it difficult for smaller vaccine developers to enter the market, which would limit competition and innovation.
• Difficulties with Vaccine Distribution and Storage: To preserve effectiveness, anthrax vaccinations frequently need particular storage settings, such as refrigeration. It can be logistically difficult to ensure appropriate vaccine storage and delivery in areas without cold chain infrastructure, which can affect vaccination efficacy and accessibility.
• Perceived Low Risk: Livestock farmers and veterinary experts may believe that there is little chance of contracting anthrax infection in areas where anthrax outbreaks are uncommon or irregular. This may cause people to become complacent and decrease the demand for anthrax vaccinations, especially when the disease is not as common.
• Cost Issues: Farmers' decisions on vaccination against anthrax may be influenced by costs associated with vaccination, including as the cost of vaccines, vaccination supplies, and veterinarian services. In areas where finances are scarce or priorities conflict, the universal acceptance of the anthrax immunisation may be hindered by its perceived cost-effectiveness.
• Efficacy and Duration of protection: Although vaccine technology has advanced, questions may still remain regarding the effectiveness and longevity of protection offered by anthrax vaccinations. The necessity for booster doses and variations in vaccine efficacy may have an effect on vaccination rates as well as the vaccine's general popularity in the market.
• Effective biosecurity measures: are crucial in preventing anthrax outbreaks in cattle herds, in addition to vaccination programmes. The efficacy of immunisation campaigns may be compromised by inadequate biosecurity measures, such as improper corpse disposal and inadequate quarantine protocols.

Global Veterinary Anthrax Vaccines Market: Segmentation Analysis

The Global Veterinary Anthrax Vaccines Market is Segmented on the basis of Product, Application, Distribution Channel, and Geography.

Veterinary Anthrax Vaccines Market, By Product

• Cell Free PA Vaccines
• Live Attenuated Vaccine

Based on Product, the market is segmented into Cell Free PA Vaccines and Live Attenuated Vaccine. The live vaccines category is expected to increase rapidly throughout the projected period. The live vaccination comprises spores from Bacillus anthracis attenuated strains, which are used to treat anthrax illness. Anthrax is produced by a big bacterium, and the major reason for anthrax immunization is the danger of inhalation infection. All animal vaccinations are live vaccines, and their use for human consumption necessitates a withholding period prior to slaughter.

Veterinary Anthrax Vaccines Market, By Application

• Animal Use
• Human Use

Based on Application, the market is segmented into Animal Use and Human Use. For the forecasted period, the animal usage sector is expected to lead the segment by application. Animals receive a large number of anthrax vaccinations. Anthrax is largely a herbivore disease. In veterinary medicine, a live unencapsulated version of B. anthracis and strain stern has been utilized to protect animals.

Veterinary Anthrax Vaccines Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies

Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Others. Hospital pharmacies have dominated the market and are predicted to rise at a high rate throughout the forecasted period. The hospital pharmacies sector market share has been driven by a series of patients arriving at a hospital emergency department and anthrax vaccinations, which are usually offered in hospital pharmacies. Anthrax vaccinations are not communicable from person to person; nonetheless, typical hospital cleanliness measures must be followed for the therapy, which may only be administered in hospitals.

Veterinary Anthrax Vaccines Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of Geography, the Global Veterinary Anthrax Vaccines Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The North American area led the worldwide Veterinary Anthrax Vaccines Market, whereas the Asia Pacific is a fast-rising region. North America dominates the market as a result of government attempts to prevent the spread of anthrax and the existence of several ongoing programs under organizations such as HHS-CDC, BARDA, ASPR, NIAID, and the FDA that are supporting market growth. Asia Pacific is a rapidly rising region as R&D funding increases. Furthermore, the presence of advanced healthcare infrastructure in Japan, as well as broad vaccine manufacturing facilities, is propelling the market growth.

Key Players

The "Global Veterinary Anthrax Vaccines Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Ceva Sante Animale, Bayer Sanidad Animal, Central Veterinary Control and Research Institute, Agrovet, Colorado Serum Company, Empresa Colombiana De Productos Veterinarios S.A., Biogenesis Bago SA, Indian Immunologicals Limited, Botswana Vaccine Institute, and Centro Diagnostico Veterinario.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• In August 2020, Elusys Therapeutics Inc. (Elusys) received Health Canada clearance for Anthim (obiltoxaximab for injection), a monoclonal antibody (mAb) anthrax antitoxin for the treatment of anthrax inhalation. It can be used to treat post-exposure prophylaxis in both adults and children.
• In August 2020, Dr. Jamie Benn Felix and the Cook Wildlife Lab team from Texas A&M University College of Veterinary Medicine & Biomedical Sciences performed pilot research for the first oral anthrax vaccination for cattle (CVMBS).

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL VETERINARY ANTHRAX VACCINES MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL VETERINARY ANTHRAX VACCINES MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL VETERINARY ANTHRAX VACCINES MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Cell Free PA Vaccines
• 5.3 Live Attenuated Vaccines

6 GLOBAL VETERINARY ANTHRAX VACCINES MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Animal Use
• 6.3 Human Use

7 GLOBAL VETERINARY ANTHRAX VACCINES MARKET, BY DISTRIBUTION CHANNEL

• 7.1 Overview
• 7.2 Hospital Pharmacies
• 7.3 Retail Pharmacies
• 7.4 Others

8 GLOBAL VETERINARY ANTHRAX VACCINES MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL VETERINARY ANTHRAX VACCINES MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Ceva Sante Animale
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Bayer Sanidad Animal
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Central Veterinary Control and Research Institute
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Agrovet
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Colorado Serum Company
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Empresa Colombiana De Productos Veterinarios S.A.
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Biogenesis Bago SA
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Indian Immunologicals Limited
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Botswana Vaccine Institute
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Centro Diagnostico Veterinario
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Research